{"transactions":[{"id":4620879,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-09-17T20:05:19.000Z","date":"2026-09-15","kind":"exercise","planned":false,"acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001477384-26-000013","document":"form4-09172026_040903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000013/form4-09172026_040903.xml","form_type":"4"}},{"id":4620878,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:05:19.000Z","date":"2026-09-15","kind":"exercise","planned":false,"acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":17995,"source":{"system":"sec-edgar","filing":"0001477384-26-000013","document":"form4-09172026_040903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000013/form4-09172026_040903.xml","form_type":"4"}},{"id":4620881,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-09-17T20:05:18.000Z","date":"2026-09-15","kind":"exercise","planned":false,"acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001477384-26-000012","document":"form4-09172026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000012/form4-09172026_040901.xml","form_type":"4"}},{"id":4620880,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:05:18.000Z","date":"2026-09-15","kind":"exercise","planned":false,"acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":17995,"source":{"system":"sec-edgar","filing":"0001477384-26-000012","document":"form4-09172026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000012/form4-09172026_040901.xml","form_type":"4"}},{"id":734013,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-17T20:05:24.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001477384-26-000011","document":"form4-06172026_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000011/form4-06172026_040615.xml","form_type":"4"}},{"id":734012,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:05:24.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":16695,"source":{"system":"sec-edgar","filing":"0001477384-26-000011","document":"form4-06172026_040615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000011/form4-06172026_040615.xml","form_type":"4"}},{"id":734015,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-17T20:05:09.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001477384-26-000010","document":"form4-06172026_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000010/form4-06172026_040604.xml","form_type":"4"}},{"id":734014,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:05:09.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":16695,"source":{"system":"sec-edgar","filing":"0001477384-26-000010","document":"form4-06172026_040604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000010/form4-06172026_040604.xml","form_type":"4"}},{"id":739749,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:42.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001477384-26-000009","document":"form4a-06122026_080638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000009/form4a-06122026_080638.xml","form_type":"4/A","original_submission_date":"2026-05-14"}},{"id":739748,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-12T20:07:42.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":2500,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001477384-26-000009","document":"form4a-06122026_080638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000009/form4a-06122026_080638.xml","form_type":"4/A","original_submission_date":"2026-05-14"}},{"id":767909,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-05-21T21:00:19.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":12000,"derivative":{"exercise_price":42.26,"exercise_date":"2027-05-19","expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001477384-26-000008","document":"form4-05212026_050512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000008/form4-05212026_050512.xml","form_type":"4"}},{"id":767908,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T21:00:19.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":39375,"source":{"system":"sec-edgar","filing":"0001477384-26-000008","document":"form4-05212026_050512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000008/form4-05212026_050512.xml","form_type":"4"}},{"id":778906,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T20:05:19.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 55,181 shares of common stock, which options vest according to their terms."}],"balance_after":42000,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001477384-26-000006","document":"form4-05142026_040515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000006/form4-05142026_040515.xml","form_type":"4"}},{"id":778905,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-14T20:05:19.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001477384-26-000006","document":"form4-05142026_040515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000006/form4-05142026_040515.xml","form_type":"4"}},{"id":802726,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":8250,"derivative":{"exercise_price":32.17,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802725,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":8250,"derivative":{"exercise_price":43.91,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802724,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":10.87,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802723,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802722,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":15.53,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802721,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802720,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":10600,"derivative":{"exercise_price":14.29,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802719,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":10600,"derivative":{"exercise_price":19.5,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802718,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":3311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":3311,"derivative":{"exercise_price":14.29,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":3311},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802717,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T22:35:46.000Z","date":"2026-04-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":3311,"derivative":{"exercise_price":19.5,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":3311},"source":{"system":"sec-edgar","filing":"0001477384-26-000005","document":"form4-04222026_100442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000005/form4-04222026_100442.xml","form_type":"4"}},{"id":802716,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":802715,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":802714,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."}],"balance_after":1300,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":802713,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":8250,"derivative":{"exercise_price":11.75,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":802712,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":3.97,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":802711,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":16510,"derivative":{"exercise_price":5.67,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":802710,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":10600,"derivative":{"exercise_price":5.22,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":802709,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:17.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":3311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":3311,"derivative":{"exercise_price":5.22,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":3311},"source":{"system":"sec-edgar","filing":"0001477384-26-000004","document":"form4-04222026_040413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000004/form4-04222026_040413.xml","form_type":"4"}},{"id":943178,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-01-08T21:02:10.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001477384-26-000001","document":"form4-01082026_090106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000001/form4-01082026_090106.xml","form_type":"4"}},{"id":943177,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T21:02:10.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":8250,"derivative":{"exercise_price":43.91,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":8250},"source":{"system":"sec-edgar","filing":"0001477384-26-000001","document":"form4-01082026_090106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738426000001/form4-01082026_090106.xml","form_type":"4"}},{"id":1037705,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-09-17T20:02:23.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."}],"balance_after":1300,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001477384-25-000004","document":"form4-09172025_080918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738425000004/form4-09172025_080918.xml","form_type":"4"}},{"id":1037704,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-17T20:02:23.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":10665,"source":{"system":"sec-edgar","filing":"0001477384-25-000004","document":"form4-09172025_080918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000147738425000004/form4-09172025_080918.xml","form_type":"4"}},{"id":1061803,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-19T20:43:12.000Z","date":"2025-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000161071725000302/form4.xml","form_type":"4"}},{"id":1061802,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-19T20:43:12.000Z","date":"2025-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15865,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.09,"expiration_date":"2032-10-06","underlying":"Common Stock","underlying_shares":15865},"source":{"system":"sec-edgar","filing":"0001610717-25-000302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000161071725000302/form4.xml","form_type":"4"}},{"id":1104950,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T21:36:59.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000243","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000161071725000243/form4.xml","form_type":"4"}},{"id":1107885,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-17T22:31:31.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":false,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001415889-25-017589","document":"form4-06172025_100627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588925017589/form4-06172025_100627.xml","form_type":"4"}},{"id":1107884,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T22:31:31.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":9365,"source":{"system":"sec-edgar","filing":"0001415889-25-017589","document":"form4-06172025_100627.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588925017589/form4-06172025_100627.xml","form_type":"4"}},{"id":1145283,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-05-16T23:00:16.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":19500,"derivative":{"exercise_price":21.15,"exercise_date":"2026-05-15","expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001415889-25-013501","document":"form4-05162025_070513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588925013501/form4-05162025_070513.xml","form_type":"4"}},{"id":1145282,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-16T23:00:16.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":35375,"source":{"system":"sec-edgar","filing":"0001415889-25-013501","document":"form4-05162025_070513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588925013501/form4-05162025_070513.xml","form_type":"4"}},{"id":1307930,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:29:38.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001415889-25-001038","document":"form4-01072025_100134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588925001038/form4-01072025_100134.xml","form_type":"4"}},{"id":1307929,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T22:29:38.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16510,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001415889-25-001038","document":"form4-01072025_100134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588925001038/form4-01072025_100134.xml","form_type":"4"}},{"id":1405044,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-09-17T22:45:02.000Z","date":"2024-09-15","kind":"exercise","planned":false,"acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."}],"balance_after":2600,"derivative":{"underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001415889-24-023552","document":"form4-09172024_100957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924023552/form4-09172024_100957.xml","form_type":"4"}},{"id":1405043,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T22:45:02.000Z","date":"2024-09-15","kind":"exercise","planned":false,"acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":3335,"source":{"system":"sec-edgar","filing":"0001415889-24-023552","document":"form4-09172024_100957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924023552/form4-09172024_100957.xml","form_type":"4"}},{"id":1475191,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-06-19T00:15:41.000Z","date":"2024-06-15","kind":"exercise","planned":false,"acquired":false,"shares":2035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2035},"source":{"system":"sec-edgar","filing":"0001415889-24-017508","document":"form4-06192024_120637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924017508/form4-06192024_120637.xml","form_type":"4"}},{"id":1475190,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-19T00:15:41.000Z","date":"2024-06-15","kind":"exercise","planned":false,"acquired":true,"shares":2035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":2035,"source":{"system":"sec-edgar","filing":"0001415889-24-017508","document":"form4-06192024_120637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924017508/form4-06192024_120637.xml","form_type":"4"}},{"id":1488354,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:28:10.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the \"Vesting Commencement Date\") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":23742,"derivative":{"exercise_price":19.17,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001610717-24-000298","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000161071724000298/form4.xml","form_type":"4"}},{"id":1520609,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-05-10T20:06:03.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":19500,"derivative":{"exercise_price":6.82,"exercise_date":"2025-05-08","expiration_date":"2034-05-07","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001415889-24-012849","document":"form4-05102024_040541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924012849/form4-05102024_040541.xml","form_type":"4"}},{"id":1520608,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-10T20:06:03.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":28875,"source":{"system":"sec-edgar","filing":"0001415889-24-012849","document":"form4-05102024_040541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924012849/form4-05102024_040541.xml","form_type":"4"}},{"id":1539909,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Series A Junior Preferred Stock","published_at":"2024-04-17T23:36:28.000Z","date":"2024-04-11","kind":"purchase","planned":false,"acquired":true,"shares":1,"price":0.01,"value":0.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 11, 2024, the Reporting Person purchased directly from the Issuer one share of the Issuer's Series A Junior Preferred Stock, par value $0.0001 per share, for a purchase price of $0.01 pursuant to a Stock Purchase Agreement, dated as of April 11, 2024, by and between the Reporting Person and the Issuer."}],"balance_after":1,"source":{"system":"sec-edgar","filing":"0001415889-24-011059","document":"form4-04172024_110421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924011059/form4-04172024_110421.xml","form_type":"4"}},{"id":1549407,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Class A Common Stock","published_at":"2024-04-04T01:37:17.000Z","date":"2023-09-01","kind":"sale","planned":false,"acquired":false,"shares":22951,"price":0.3746,"value":8597.4446,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" and does not represent a discretionary trade by the Reporting Person."}],"balance_after":77541,"source":{"system":"sec-edgar","filing":"0001415889-24-010243","document":"form4-04042024_010411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000141588924010243/form4-04042024_010411.xml","form_type":"4"}},{"id":1685430,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-01-05T21:57:27.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":6030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6030,"derivative":{"underlying":"Common Stock","underlying_shares":6030},"source":{"system":"sec-edgar","filing":"0001209191-24-001049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919124001049/doc4.xml","form_type":"4"}},{"id":1685429,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:57:27.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":16510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16510,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":16510},"source":{"system":"sec-edgar","filing":"0001209191-24-001049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919124001049/doc4.xml","form_type":"4"}},{"id":1709864,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2044,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2044},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709863,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3676,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":135.63,"expiration_date":"2032-05-13","underlying":"Common stock","underlying_shares":3676},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709862,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":147.5,"expiration_date":"2031-05-14","underlying":"Common stock","underlying_shares":3462},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709861,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3171,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":160.33,"expiration_date":"2030-05-15","underlying":"Common stock","underlying_shares":3171},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709860,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7038,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":64.38,"expiration_date":"2029-05-20","underlying":"Common stock","underlying_shares":7038},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709859,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":56.77,"expiration_date":"2028-05-18","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709858,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":66.6,"expiration_date":"2027-05-19","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709857,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":38.82,"expiration_date":"2026-05-20","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709856,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9260,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":39.94,"expiration_date":"2025-05-15","underlying":"Common stock","underlying_shares":9260},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709855,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":42.97,"expiration_date":"2024-01-10","underlying":"Common stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1709854,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T18:10:54.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29003,"price":229,"value":6641687.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-070863","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070863/ownership.xml","form_type":"4"}},{"id":1743884,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-13T23:48:09.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from November 10, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":25000,"derivative":{"exercise_price":15,"expiration_date":"2033-11-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-23-000347","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000161071723000347/form4.xml","form_type":"4"}},{"id":1778827,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-09-18T22:11:39.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date."}],"balance_after":3900,"derivative":{"underlying":"Common Stock","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001209191-23-049806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919123049806/doc4.xml","form_type":"4"}},{"id":1778826,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-09-18T22:11:39.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":2035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":2035,"derivative":{"underlying":"Common Stock","underlying_shares":2035},"source":{"system":"sec-edgar","filing":"0001209191-23-049806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919123049806/doc4.xml","form_type":"4"}},{"id":1778825,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-18T22:11:39.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as of 1/36 of the total shares monthly beginning on October 15, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":10600,"derivative":{"exercise_price":19.5,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001209191-23-049806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919123049806/doc4.xml","form_type":"4"}},{"id":1778824,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-18T22:11:39.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":3311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/4 of the total shares monthly beginning on October 6, 2023 and each month thereafter until fully vested on January 6, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":3311,"derivative":{"exercise_price":19.5,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":3311},"source":{"system":"sec-edgar","filing":"0001209191-23-049806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919123049806/doc4.xml","form_type":"4"}},{"id":1870677,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T18:21:34.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":2044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units and will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest in full on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":31047,"source":{"system":"sec-edgar","filing":"0001203311-23-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000061/edgardoc.xml","form_type":"4"}},{"id":1884528,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-19T20:05:38.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":13500,"derivative":{"exercise_price":17.11,"exercise_date":"2024-05-17","expiration_date":"2033-05-16","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001209191-23-030956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919123030956/doc4.xml","form_type":"4"}},{"id":1884527,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T20:05:38.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":22375,"source":{"system":"sec-edgar","filing":"0001209191-23-030956","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919123030956/doc4.xml","form_type":"4"}},{"id":2019889,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2023-02-14T02:00:26.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":435000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48 of the Option vests in equal monthly installments as measured from January 1, 2023. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":435000,"derivative":{"exercise_price":1.49,"expiration_date":"2033-02-08","underlying":"Class A Common Stock","underlying_shares":435000},"source":{"system":"sec-edgar","filing":"0001209191-23-008958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919123008958/doc4.xml","form_type":"4"}},{"id":2154050,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Class A Common Stock","published_at":"2022-09-20T22:12:46.000Z","date":"2022-09-02","kind":"sale","acquired":false,"shares":20908,"price":1.7752,"value":37115.8816,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $1.74 to $1.83 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":100492,"source":{"system":"sec-edgar","filing":"0001209191-22-050778","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122050778/doc4.xml","form_type":"4"}},{"id":2231432,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"disposition_to_issuer","acquired":false,"shares":58995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48 of the Option vests in equal monthly installments as measured from 11/15/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":0,"derivative":{"exercise_price":10.02,"expiration_date":"2028-11-14","underlying":"Class A Common Stock","underlying_shares":58995},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2231431,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":58995,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the \"Option Repricing\"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022.  Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option.  The Option Repricing does not apply to options held by non-employee directors of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48 of the Option vests in equal monthly installments as measured from 11/15/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":58995,"derivative":{"exercise_price":1.845,"expiration_date":"2028-11-14","underlying":"Class A Common Stock","underlying_shares":58995},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2231430,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"disposition_to_issuer","acquired":false,"shares":148754,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48 of the Option vests in equal monthly installments as measured from 10/1/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":0,"derivative":{"exercise_price":10.02,"expiration_date":"2028-10-29","underlying":"Class A Common Stock","underlying_shares":148754},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2231429,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":148754,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the \"Option Repricing\"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022.  Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option.  The Option Repricing does not apply to options held by non-employee directors of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48 of the Option vests in equal monthly installments as measured from 10/1/2018. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":148754,"derivative":{"exercise_price":1.845,"expiration_date":"2028-10-29","underlying":"Class A Common Stock","underlying_shares":148754},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2231428,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"disposition_to_issuer","acquired":false,"shares":241000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48 of the Option vests in equal monthly installments as measured from 1/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":0,"derivative":{"exercise_price":22.07,"expiration_date":"2030-02-25","underlying":"Class A Common Stock","underlying_shares":241000},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2231427,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":241000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the \"Option Repricing\"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022.  Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option.  The Option Repricing does not apply to options held by non-employee directors of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48 of the Option vests in equal monthly installments as measured from 1/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":241000,"derivative":{"exercise_price":1.845,"expiration_date":"2030-02-25","underlying":"Class A Common Stock","underlying_shares":241000},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2231426,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"disposition_to_issuer","acquired":false,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":0,"derivative":{"exercise_price":13.97,"expiration_date":"2031-01-26","underlying":"Class A Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2231425,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2022-06-15T23:15:56.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":260000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the \"Option Repricing\"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022.  Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option.  The Option Repricing does not apply to options held by non-employee directors of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":260000,"derivative":{"exercise_price":1.845,"expiration_date":"2031-01-26","underlying":"Class A Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-22-037114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122037114/doc4.xml","form_type":"4"}},{"id":2268742,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-05-17T19:33:33.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":3676,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3676,"derivative":{"exercise_price":135.63,"exercise_date":"2023-05-13","expiration_date":"2032-05-13","underlying":"Common Stock","underlying_shares":3676},"source":{"system":"sec-edgar","filing":"0000899243-22-018465","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322018465/doc4.xml","form_type":"4"}},{"id":2268741,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T19:33:33.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":1503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest in full on May 13, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":29003,"source":{"system":"sec-edgar","filing":"0000899243-22-018465","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322018465/doc4.xml","form_type":"4"}},{"id":2273490,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-05-13T00:30:00.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":9000,"derivative":{"exercise_price":21.38,"exercise_date":"2023-05-11","expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-22-028699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122028699/doc4.xml","form_type":"4"}},{"id":2273489,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T00:30:00.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":17875,"source":{"system":"sec-edgar","filing":"0001209191-22-028699","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919122028699/doc4.xml","form_type":"4"}},{"id":2457851,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2021-12-28T23:50:35.000Z","date":"2021-12-23","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48 of the Option vests in equal monthly installments as measured from 12/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Early Exercise is not permitted."}],"balance_after":260000,"derivative":{"exercise_price":3.18,"expiration_date":"2031-12-22","underlying":"Class A Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-21-071425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919121071425/doc4.xml","form_type":"4"}},{"id":2571930,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Class A Common Stock","published_at":"2021-09-14T01:46:26.000Z","date":"2021-09-09","kind":"grant","acquired":true,"shares":115400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock are to be acquired upon the vesting of a restricted stock unit award granted to the Reporting Person. The restricted stock unit award shall vest as follows: vest over two years (vesting commencement date = September 1, 2021), with a one-year cliff as follows: on the first anniversary of the vesting commencement date, 50% of the restricted stock unit award shall vest, and on the second anniversary of the vesting commencement date, 50% of the restricted stock unit award shall vest. In total, 100% of the restricted stock unit award shall be vested on the second anniversary of the vesting commencement date."}],"balance_after":121400,"source":{"system":"sec-edgar","filing":"0001209191-21-055809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919121055809/doc4.xml","form_type":"4"}},{"id":2708017,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-05-19T01:17:35.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":9000,"derivative":{"exercise_price":18.27,"exercise_date":"2022-05-14","expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-21-033847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919121033847/doc4.xml","form_type":"4"}},{"id":2708016,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-19T01:17:35.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":14875,"source":{"system":"sec-edgar","filing":"0001209191-21-033847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919121033847/doc4.xml","form_type":"4"}},{"id":2708749,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-05-18T19:27:29.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":3462,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3462,"derivative":{"exercise_price":147.5,"exercise_date":"2022-05-14","expiration_date":"2031-05-14","underlying":"Common Stock","underlying_shares":3462},"source":{"system":"sec-edgar","filing":"0001203311-21-000032","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331121000032/edgardoc.xml","form_type":"4"}},{"id":2708748,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-18T19:27:29.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":1402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"date","element":"transactionDate","label":"F2","text":"These restricted stock units shall vest in full on May 14, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":27500,"source":{"system":"sec-edgar","filing":"0001203311-21-000032","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331121000032/edgardoc.xml","form_type":"4"}},{"id":2890253,"issuer":{"id":91940,"kind":"organization","name":"Atreca, Inc.","symbol":"BCEL"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee stock option (right to buy)","published_at":"2021-01-30T01:28:43.000Z","date":"2021-01-27","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time."}],"balance_after":260000,"derivative":{"exercise_price":13.97,"expiration_date":"2031-01-26","underlying":"Class A Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-21-006340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919121006340/doc4.xml","form_type":"4"}},{"id":3142650,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2020-05-20T00:00:23.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":15.43,"exercise_date":"2021-05-15","expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-030749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919120030749/doc4.xml","form_type":"4"}},{"id":3142649,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T00:00:23.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11875,"source":{"system":"sec-edgar","filing":"0001209191-20-030749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1477384/000120919120030749/doc4.xml","form_type":"4"}},{"id":3143484,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-05-19T19:10:51.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":3171,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3171,"derivative":{"exercise_price":160.33,"exercise_date":"2021-05-15","expiration_date":"2030-05-15","underlying":"Common Stock","underlying_shares":3171},"source":{"system":"sec-edgar","filing":"0001203311-20-000049","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331120000049/edgardoc.xml","form_type":"4"}},{"id":3143483,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":37244,"kind":"person","name":"Orwin John A","position":1,"cik":"0001477384","reported_name":"Orwin John A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-19T19:10:51.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":1335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"date","element":"transactionDate","label":"F2","text":"These restricted stock units shall vest in full on May 15, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":26098,"source":{"system":"sec-edgar","filing":"0001203311-20-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331120000049/edgardoc.xml","form_type":"4"}}],"next_cursor":"2020-05-19T19:10:51.000000Z,3143483"}